Vinay Prasad departs FDA | STAT
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA clears way for Sarepta Therapeutics to use Duchenne drug in some patients
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middle
Jennifer Hill Blair recognized the Cincinnati number on her buzzing phone and slipped out of the school meeting,…
Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA rejects Replimune skin cancer therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Sarepta Therapeutics’ Duchenne therapy crisis has a clear lesson
In a matter of a few days last week, Sarepta Therapeutics announced major layoffs, acknowledged the death of…
Sarepta Therapeutics crisis is huge blow to Duchenne families, company
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Patient dies in Sarepta gene therapy trial, adding to safety concerns
A 51-year-old man died last month after receiving an experimental gene therapy developed by Sarepta Therapeutics for an…
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA rejects Capricor’s Duchenne cell therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Kennedy abruptly cancels U.S. Preventive Services Task Force meeting
WASHINGTON — Health secretary Robert F. Kennedy Jr. has abruptly canceled a meeting of a key expert panel that…